Intra-Cellular Therapies Management
Management criteria checks 3/4
Intra-Cellular Therapies' CEO is Sharon Mates, appointed in May 2002, has a tenure of 21.83 years. total yearly compensation is $9.23M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.08% of the company’s shares, worth $73.23M. The average tenure of the management team and the board of directors is 5.5 years and 10.2 years respectively.
Key information
Sharon Mates
Chief executive officer
US$9.2m
Total compensation
CEO salary percentage | 9.2% |
CEO tenure | 21.8yrs |
CEO ownership | 1.1% |
Management average tenure | 5.5yrs |
Board average tenure | 10.2yrs |
Recent management updates
Recent updates
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Dec 24Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment
Dec 21Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space
Nov 08We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Aug 06We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right
Jun 15Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow
Jun 04FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression
May 03We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Mar 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$140m |
Sep 30 2023 | n/a | n/a | -US$155m |
Jun 30 2023 | n/a | n/a | -US$184m |
Mar 31 2023 | n/a | n/a | -US$228m |
Dec 31 2022 | US$9m | US$849k | -US$256m |
Sep 30 2022 | n/a | n/a | -US$298m |
Jun 30 2022 | n/a | n/a | -US$321m |
Mar 31 2022 | n/a | n/a | -US$304m |
Dec 31 2021 | US$7m | US$794k | -US$284m |
Sep 30 2021 | n/a | n/a | -US$259m |
Jun 30 2021 | n/a | n/a | -US$237m |
Mar 31 2021 | n/a | n/a | -US$232m |
Dec 31 2020 | US$5m | US$767k | -US$227m |
Sep 30 2020 | n/a | n/a | -US$207m |
Jun 30 2020 | n/a | n/a | -US$187m |
Mar 31 2020 | n/a | n/a | -US$160m |
Dec 31 2019 | US$5m | US$745k | -US$148m |
Sep 30 2019 | n/a | n/a | -US$148m |
Jun 30 2019 | n/a | n/a | -US$155m |
Mar 31 2019 | n/a | n/a | -US$154m |
Dec 31 2018 | US$4m | US$723k | -US$155m |
Sep 30 2018 | n/a | n/a | -US$145m |
Jun 30 2018 | n/a | n/a | -US$126m |
Mar 31 2018 | n/a | n/a | -US$106m |
Dec 31 2017 | US$5m | US$702k | -US$98m |
Compensation vs Market: Sharon's total compensation ($USD9.23M) is about average for companies of similar size in the US market ($USD7.72M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
CEO
Sharon Mates (70 yo)
21.8yrs
Tenure
US$9,232,857
Compensation
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 21.8yrs | US$9.23m | 1.08% $ 73.2m | |
President | no data | US$3.48m | 0% $ 0 | |
Executive VP & Chief Medical Officer | 5.6yrs | US$3.46m | 0.020% $ 1.4m | |
EVP & Chief Commercial Officer | 5.4yrs | US$3.50m | 0.031% $ 2.1m | |
Senior VP & Chief Scientific Officer | 8.3yrs | US$2.13m | no data | |
Vice President of Corporate Communications & Investor Relations | 10yrs | US$1.38m | no data | |
Senior VP & Chief Compliance Officer | 4.7yrs | no data | no data | |
Senior VP & Head of Regulatory Affairs | 5.5yrs | no data | no data | |
Senior VP of Market Access | 5yrs | no data | no data | |
Senior VP & Head of Clinical Development | 1.9yrs | no data | no data |
5.5yrs
Average Tenure
60yo
Average Age
Experienced Management: ITCI's management team is seasoned and experienced (5.5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 10.6yrs | US$9.23m | 1.08% $ 73.2m | |
Independent Director | 10.2yrs | US$741.17k | 0.10% $ 6.9m | |
Lead Independent Director | 10.2yrs | US$774.41k | 0.0099% $ 670.2k | |
Independent Director | 10.6yrs | US$743.26k | 0.041% $ 2.8m | |
Chairman of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Member of Medical Advisory Board | no data | no data | no data | |
Independent Director | 1.9yrs | US$716.63k | 0% $ 0 |
10.2yrs
Average Tenure
70yo
Average Age
Experienced Board: ITCI's board of directors are seasoned and experienced ( 10.2 years average tenure).